Navigation Links
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
Date:2/23/2009

TOKYO and INDIANAPOLIS, Feb. 23 /PRNewswire-FirstCall/ -- Heart patients with acute coronary syndrome (ACS) undergoing an artery-opening procedure will soon have a new treatment option to help prevent heart attacks. Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted marketing authorization for EFIENT(R) (pronounced Ef-ee-ent) (prasugrel) for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (PCI).

The approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency on December 18, 2008.

"This European approval is good news for doctors and patients since more than 700,000 people die from heart attacks in the European Union each year," said Takashi Shoda, president and chief executive officer of Daiichi Sankyo Co., Ltd. "We believe Efient will become an important new treatment for patients with ACS undergoing PCI, a severe disease with potentially life-threatening consequences."

Prasugrel works by reducing the tendency of platelets, the blood particles responsible for clotting, from sticking or clumping together. By blocking a specific receptor (P2Y12 adenosine diphosphate) on the platelet surface, prasugrel prevents platelets from clumping, which can result in clogged arteries and may lead to heart attack.

"The approval of Efient helps to meet an important medical need. Survivors of heart attacks have a substantial risk of suffering from one or more additional heart attacks," said John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Lilly. "This action is a major step forward in giving healthcare professionals and patients in European countri
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
2. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
3. Registration Open for OpenClinica European Summit - April 14, 2009
4. Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project
5. Myngle Best ICT Company at the European Ventures Summit
6. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
7. Kuvan Receives Marketing Approval in the European Union
8. BioLife Solutions Granted European Biopreservation Patent
9. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
10. Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System
11. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Research and Markets ( ... "Global Bioinformatics Market Outlook 2019" report to their ... mark of around US$ 3.7 Billion in 2013 with ... around 19% during 2015-2019 The report is ... of global developments and opportunities listed in the section ...
(Date:4/21/2015)... 21, 2015 Research and Markets ... the "Complete 2015-16 Induced Pluripotent Stem Cell ... Stem cell research and experimentation have ... as stem cells have the unique ability to ... nature allows them to differentiate into a wide ...
(Date:4/21/2015)... , April 21, 2015 The ... $313.0 million in 2014 to $605.1 million by 2019, at ... Browse through the TOC of ... analysis of the industry trends and segments, with help ... Early buyers will receive 10% ...
(Date:4/21/2015)... Contract Research Organization XenoTech, LLC , a division of ... ft2 facility. The planned move will double the size ... St. in Lenexa, KS. The new facility, boasting nearly ... remain in the Kansas City metro area, just blocks away ... ago. Remaining in the Kansas City area maintains the ...
Breaking Biology Technology:Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 2Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 3Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3
... 7 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... to present a corporate overview at the,ThinkEquity Partners, G5: ... p.m. Eastern Time (10:30 a.m. Pacific Time) at the ... the live audio broadcast or the subsequent archived,recording, log ...
... and Risk ... Distant Sites, REHOVOT, Israel and NEW YORK, September 7 ... in the field of,microRNA and RNAi, announced today it will ... significant potential of microRNA,profiles to develop a diagnostic test for ...
... 5:30-7:30 p.m. (ET), SAN DIEGO, Sept. 7 ... developing products for,minimally disruptive surgical treatments for the spine, ... institutional investors and,analysts at the Waldorf=Astoria Hotel in New ... to 7:30 p.m. ET. The reception will be ...
Cached Biology Technology:Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 3NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 4NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 5NuVasive to Host Investor Reception on September 11, 2007 2NuVasive to Host Investor Reception on September 11, 2007 3NuVasive to Host Investor Reception on September 11, 2007 4
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... United States and Europe has identified a single genetic mutation ... with and without diabetes. Albuminuria is a condition caused by ... is an indication of kidney disease. The research team, ... association studies to identify missense variant (I2984V) in the CUBN ...
... tiniest pollution particles which we take in with ... people more vulnerable to cardiovascular and respiratory problems. While ... showing exactly how it does so has been challenging. ... Environmental Health Perspectives , scientists showed that in ...
... an estimated 10,000 shipping containers fall off container ships at ... for months, most eventually sink to the seafloor. No one ... deep seafloor. From March 8 to March 10, 2011, ... National Marine Sanctuary (MBNMS) will use a robotic submarine to ...
Cached Biology News:Gene variant influences chronic kidney disease risk 2Pinpointing air pollution's effects on the heart 2Pinpointing air pollution's effects on the heart 3MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea 2MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea 3
Recombinant Mouse Noggin...
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Human VASA Biotinylated Affinity Purified PAb...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Biology Products: